このエントリーをはてなブックマークに追加
ID 53996
JaLCDOI
FullText URL
Author
Yasunaka, Tetsuya
Wada, Nozomu
Morimoto, Yuki
Fujioka, Shin-ichi
Toshimori, Junichi
Kobashi, Haruhiko
Kariyama, Kazuya
Morimoto, Yoichi
Takayama, Hiroki
Seno, Tomonori
Takaguchi, Koichi
Moriya, Akio
Miyatake, Hirokazu
Okamoto, Ryoichi
Yabushita, Kazuhisa
Yamamoto, Kazuhide
Abstract
Chronic hepatitis B (CHB) leads to cirrhosis and hepatocellular carcinoma (HCC). With a cohort of 1,206 CHB patients who visited Okayama University Hospital and related hospitals in 2011 and 2012, we compared the incidence rates of HCC among the patients grouped by age, hepatitis B virus (HBV) DNA, hepatitis B e antigen (HBeAg), and treatment. HCCs were observed in 115 patients with the median observation period of 1,687 days. Among the HCC patients aged ≥ 35 years, HBV DNA ≥ 4 log copies/mL and positive HBeAg at diagnosis (n=184), the HCC incidence rate was 8.4% at 5 years in the entecavir (ETV)-treated patients, 21.8% in the lamivudine (LVD)-treated patients, and 26.4% among the patients not treated with drugs. The cumulative HCC incidence was significantly reduced in the ETV-treated patients compared to those treated with LVD or not treated (p=0.013). Among the patients aged ≥ 35 years with HBV DNA ≥ 4 log copies/mL and negative HBeAg (n=237), the cumulative HCC incidence was 14.6% in 5 years in ETV group and 13.9% among those not treated with a drug (p>0.05). Only small numbers of HCCs occurred in other patients. In CHB patients aged≥35 years with HBV DNA ≥4 log copies/mL and positive HBeAg, ETV treatment is recommended for the suppression of HCC development.
Keywords
entecavir
hepatitis B virus
lamivudine
hepatocellular carcinoma
Amo Type
Original Article
Published Date
2016-02
Publication Title
Acta Medica Okayama
Volume
volume70
Issue
issue1
Publisher
Okayama University Medical School
Start Page
1
End Page
12
ISSN
0386-300X
NCID
AA00508441
Content Type
Journal Article
language
英語
Copyright Holders
CopyrightⒸ 2016 by Okayama University Medical School
File Version
publisher
Refereed
True
PubMed ID
Web of Sience KeyUT